PIK3CB and neoplasm: Inhibition of this RAS binding domain with the small molecule agent rigosertib impairs the interaction between RAS and RAF, as well as Ral and PI3K, simultaneously incapacitating several downstream RAS effectors and impairing tumor growth in vitro and in vivo (120).